Muscle-Invasive Bladder Cancer: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 159: | Line 159: | ||
===== Adjuvant ===== | ===== Adjuvant ===== | ||
* '''<span style="color:#ff00ff">CheckMate 274 (adjuvant nivolumab)</span>''' | * '''<span style="color:#ff00ff">CheckMate 274 (adjuvant nivolumab)</span>''' | ||
** '''Population: 709 patients with high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma of the bladder, ureter, or renal pelvis, with or without neoadjuvant cisplatin-based therapy''' | ** '''<span style="color:#ff0000">Population: 709 patients with high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma of the bladder, ureter, or renal pelvis, with or without neoadjuvant cisplatin-based therapy</span>''' | ||
*** '''<span style="color:#ff0000">High risk defined as</span>''' | *** '''<span style="color:#ff0000">High risk defined as</span>''' | ||
**** '''<span style="color:#ff0000">Pathological stage pT3, pT4a, or pN+ and patient not eligible for or declined adjuvant cisplatin-based combination therapy for patients without previous neoadjuvant cisplatin-based chemotherapy</span>''' | **** '''<span style="color:#ff0000">Pathological stage pT3, pT4a, or pN+ and patient not eligible for or declined adjuvant cisplatin-based combination therapy for patients without previous neoadjuvant cisplatin-based chemotherapy</span>''' | ||